Plasma lathosterol measures rates of cholesterol synthesis and efficiency of dietary phytosterols in reducing the plasma cholesterol concentration

Valéria Sutti Nunes, Angela de Oliveira Godoy Ilha, Guilherme da Silva Ferreira, Renata de Paula Assim Bombo, Milessa Silva Afonso, Maria Silvia Ferrari Lavrador, Roberta Marcondes Machado, Edna Regina Nakandakare, Eder Carlos Rocha Quintão, Ana Maria Lottenberg

**Method:** The authors studied 38 non-obese volunteers (58±12 years; Low-Density Lipoprotein Cholesterol – LDL-C ≥ 130 mg/dL) randomly assigned to consume 400 mL/day of soy milk (Control phase) or soy milk + PS (1.6 g/day) for four weeks in a double-blind, cross-over study. PS and lathosterol were measured in plasma by gas chromatography coupled to mass spectrophotometry.

**Results:** PS treatment reduced plasma total cholesterol concentration (−5.5 %, p < 0.001), LDL-C (−7.6 %, p < 0.001), triglycerides (−13.6 %, p < 0.0085), and apolipoprotein B (apo B) (−6.3 %, p < 0.008), without changing high density lipoprotein cholesterol (HDL-C concentration), but plasma lathosterol, campesterol and sitosterol expressed per plasma cholesterol increased.

**Conclusions:** The lathosterol-to-cholesterol plasma ratio predicted the plasma cholesterol response to PS feeding. The highest plasma lathosterol concentration during the control phase was associated with a lack of response of plasma cholesterol during the PS treatment period. Consequently, cholesterol synthesis in non-responders to dietary PS being elevated in the control phase indicates these cases resist to further synthesis rise, whereas responders to dietary PS, having in the control phase synthesis values lower than non-responders, expand synthesis on PS treatment increased.

**Keywords:** Phytosterols, Lathosterol, Phytosterols, Diet

**Introduction**

It is well known that dietary Phytosterols (PS) reduce total plasma cholesterol and low-density lipoproteins cholesterol (LDL-C) due to displacement of cholesterol from the intestinal lumen micelles and for molecular actions inside enterocytes and hepatocytes. Moreover, it was also demonstrated that PS could induce LDL receptor expression and lower plasma endothelin-1 independently of plasma LDL-C reductions contributing to the comprehension of plant sterol’s effects on endothelial function and prevention of cardiovascular diseases. Because of the beneficial effects on lipid profile, the 2001 National Cholesterol Education Program (NCEP ATP-III) (National Cholesterol Education Program Expert Panel) included dietary PS in the treatment for moderate hypercholesterolemia. However, after this guideline publication, some reports claimed high PS plasma and tissue concentrations related to cardiovascular risk increase. Nevertheless, Bombo et al. showed that PS feeding did not accumulate sterols in the aortic valve or arterial wall in LDL receptor knockout mice fed a high saturated fat diet. Furthermore, PS treatment prevented atherosclerotic lesion development in hypercholesterolemia mice models.

The recommendation of PS supplementation to treat hypercholesterolemia is 2 g/day. Some authors have shown that amounts from 0.8 g/day were effective in reducing cholesterol. It is not possible to reach the recommended PS intake only with the consumption of vegetable foods, as their habitual diet contains 150–400 mg/day. A review of approximately 40 studies found that the dose of 2 g/day resulted in...
a 10% reduction in LDL-C and that larger amounts do not potentiate this action. 15

Plasma concentrations of PS and of non-cholesterol sterols precursors of cholesterol synthesis, respectively markers of intestinal cholesterol absorption and of body’s cholesterol synthesis have been used as markers of atherosclerotic cardiovascular disease. 16–21 Nonetheless, objections were raised against the interpretation of results utilizing plasma PS measurements as markers of intestinal cholesterol absorption and of non-cholesterol precursors as markers of cholesterol synthesis. In this regard, high plasma PS were considered inappropriate cholesterol absorption surrogates because dietary PS lowered the intestinal cholesterol absorption rate. 22 Furthermore, in an investigation on moderate human hypercholesterolemia, the plasma campesterol/cholesterol ratio did not differ between groups that absorb different amounts of cholesterol simultaneously measured by the gold standard radioactive or isotopic cholesterol procedure. 23 Therefore, the elevation of plasma PS may represent a defect in the body’s efficiency to re-excrete PS and not an increase in the intestinal absorption of dietary cholesterol. 24 Consequently, increased PS intestinal uptake relationship to premature atherosclerosis in humans is unlikely. Accordingly, Cardiovascular Disease (CVD) mortality is related reciprocally with plasma PS (sitosterol) as a cholesterol absorption marker, and the high desmosterol/sitosterol ratio suggests high cholesterol synthesis and low absorption associated with high total and CVD mortality. 25 Nonetheless, low serum lathosterol, but not sterol absorption markers, have been associated with increased CVD. 26 In contrast, increased excretion of endogenous cholesterol, which represents increased cholesterol synthesis, seems negatively associated with carotid intima-media thickness. 27 In one study in children, dietary PS altered the serum PS concentration but not concentrations of cholesterol synthesis precursors. 28 Contrarily, in one study on low cholesterol synthesis cases during the basal period, high intestinal sitosterol absorption occurred on PS feeding, 29 but this was not mentioned in another study. 30 Consequently, there are often limitations on the use of serum non-cholesterol sterol synthesis and absorption markers on cardiovascular risk evaluation. 30

To investigate the reasons for the mentioned published discrepancies, the authors aimed at measuring plasma concentrations of non-cholesterol sterol as a precursor of cholesterol synthesis (lathosterol), and PS as markers of intestinal absorption of cholesterol in the control phase and on the PS feeding phase.

Materials and methods

Study design

This study shares previously published casuistic where the authors evaluated the effect of PS on biomarkers involved in atherosclerosis progression and whether these effects are independent of alterations in plasma LDL-C levels. 8 This is a randomized, double-blind dietary intervention trial lasting 4 weeks each study period. Initially, all the participants were submitted to a 3-week run-in period in which they received the control product (soy milk) to test adherence to the protocol. After the baseline period, participants were randomly assigned to control or to PS treatment phases for 4-weeks; after that, a reverse sequence was immediately carried out. The Control group received 400 mL of soy milk daily; the PS group received 400 mL of soy milk enriched with PS (1.6 g/day) being 78% β-sitosterol-ester, 13% sitostanol-ester, 5.3% campesterol-ester, and 0.5% campestanol-ester. Control and PS soy milk were produced at Unilever Bestfoods Netherlands. The analysis of the composition of the milk was performed by Unilever Bestfoods (Table 1).

Blood samples for biochemical analysis from fasting participants were drawn on the last day of each period. All participants were advised to maintain their body weight on a normocaloric diet based on the NCEP-ATP III recommendation: total energy represented as fat (30%), being less than < 10% as saturated fat, and < 300 mg cholesterol/day. They were advised not to consume products enriched with PS during the study. Nutritional monitoring was performed by a registered dietitian using a 24-hour dietary recall to estimate food intake and to ensure diet adherence. Soy milk was supplied weekly on the same day of body weight measurement. Participants were instructed to consume soy milk or PS-enriched soy milk twice daily at lunch and dinner.

Participants (n = 38; female 31 and male 7), aged 38–77 years, were recruited in the Dyslipidemia Outpatient Unit of the Endocrinology and Metabolism Service and staff members of the Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, and participated in body weight and height screenings. Blood samples were drawn for the lipid profile determination. Exclusion criteria were Body Mass Index (BMI) between 20 and 30 kg/m², total cholesterol between 200–300 mg/dL, LDL-C ≥ 130 mg/dL, and triglycerides ≤ 250 mg/dL (Table 2). Exclusion criteria were obesity, use of lipid-lowering medication or a prescribed diet in the previous month, alcohol abuse or illicit drug users, pregnancy or breastfeeding, smoking, diabetes mellitus, hypothyroidism, renal or hepatic diseases, or participation in another lifestyle or pharmaceutical intervention study. All subjects provided informed written consent. The Ethics in Research Committee of the Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, approved the study protocol (CAPesq n° 112/06). All methods were in accordance with the approved guidelines and in agreement with the Ethical Principles for Medical Research Involving Human Subjects as stated by the Declaration of Helsinki.

Lipid profile

After fasting for 12 hours, blood samples were transferred into tubes containing Ethylenediamine Tetracetic Acid (EDTA). Plasma was immediately separated by centrifugation and the following preservatives

| Table 1 |
| --- |
| Soy milk nutritional composition per portion (200 mL). |

| Nutritional composition | Soy milk | Soy milk + PS |
| --- | --- | --- |
| Energy (kcal) | 138 | 144 |
| Protein (g) | 6.5 | 6.5 |
| Total fat (g) | 2.4 | 5.0 |
| Polyunsaturated fat | 2.3 | 2.5 |
| Monounsaturated fat | 1.0 | 1.1 |
| Saturated fat | 0.7 | 0.9 |
| Trans fatty acid | 0 | 0 |
| Cholesterol (mg) | 0 | 0 |
| Carbohydrates (g) | 18.2 | 18.2 |
| Total sugar | 14.1 | 14.1 |
| Lactose | 0 | 0 |
| Phytoesterol (g) | 0 | 0.8 |
| β-sitosterol-ester | – | 0.63 |
| Sitostanol-ester | – | 0.10 |
| Campesterol-ester | – | 0.05 |
| Campestanol-ester | – | 0.005 |
| Sodium (g) | 0.1 | 0.1 |

Table 2

| Parameter Mean ± SD |
| --- |
| n | 38 |
| Age (years) | 58 ± 12 |
| Weight (Kg) | 64 ± 10 |
| BMI (kg/m²) | 25.3 ± 2.4 |
| Total cholesterol (mg/dL) | 245 ± 34 |
| Triglycerides (mg/dL) | 141 ± 53 |
| LDL-C (mg/dL) | 165 ± 34 |
| HDL-C (mg/dL) | 49 ± 12 |

BMI, Body Mass Index; LDL-C, Low-Density Lipoprotein Cholesterol; HDL-C, High Density Lipoprotein Cholesterol.
were added: 0.25% chloramphenicol plus 0.5% gentamycin (20 μL/mL), 2 mmol benzamidine/L (5 μL/mL), 10 mmol phenyl-methyl-sulfonyl fluoride/L (0.5 μL/mL), and aprotinin (0.5 μL/mL).

Plasma lipid concentrations (total cholesterol, HDL-C, and triglycerides) were measured enzymatically using a COBAS MIRA (Roche Diagnostics, Basel/Basel, Switzerland), using kits from Roche Diagnostics (Mannheim, Germany). HDL-C was measured after apolipoprotein (apo) B-containing lipoprotein precipitation by dextran sulfate and magnesium chloride 2 M (1:1) (50 μL/500 μL of plasma) solution. The LDL-C was calculated according to the Friedewald formula, and apo B was measured by the turbidimetric method (Randox Laboratories, United Kingdom).

Steros analyses

Plasma lathosterol, campesterol, and sitosterol were measured by Gas Chromatography (GC) coupled to a Mass Spectrophotometer (MS) (Shimadzu GCMS-QP2010 Plus, Kyoto, Japan), with the software GCMS solution version 2.5.33 Plasma samples (100 μL) added 5α-cholestane (1 μg) as the internal standard were hydrolyzed with KOH in ethanol (1 mol/L, 1 mL) at 60°C (1 h) and extracted with hexane. Sterols were derivatized with a silylating solution of pyridine and BSTFA (N, O-bis [trimethylsilyl] trifluoroacetamide) +1% TMCS (trimethylchlorosilane) (1:1, v/v) (Supelco 33155-U) for 1 h at 60°C. The derivatized sample (1 μL) was injected into a gas chromatograph coupled to a mass spectrometer (Shimadzu GCMS-QP2010, Kyoto, Japan). Efficient sterol separation was achieved in a Restek capillary column (100% dimethyl polysiloxane – Rxi13323) that was 30 m long, had a 0.25 mm internal diameter, contained helium as the mobile phase, and had a constant linear velocity of 45.8 cm/s with an oven temperature at 280°C. The mass spectrometer was operated in electronic impact mode at an ionization voltage of 70 eV with a source temperature of 300°C for the ions and the interface. Single Ion Monitoring (SIM) was carried out by monitoring m/z = 109, 149 and 217 for 5α-cholestanate, m/z = 213, 255 and 458 for lathosterol, m/z = 129, 343 and 382 for campesterol and m/z = 129, 357 and 396 for sitosterol enabling greater sensitivity in quantification. Quantification was based on the Total Ion Chromatogram (TIC) with correction by the internal standard 5α-cholestanate, and identification was based on comparison with the retention times and mass spectra of the standard curve. The coefficient of variation of the method was: lathosterol 5%, campesterol 6%, and sitosterol 7%.

Statistical analysis

Comparisons between the Control and PS groups were by paired Student’s t-test. The influence of the degree of hypercholesterolemia over the PS response and PS response patterns related to LDL-C was by unpaired Student’s t-test. Data are shown as means and standard deviation. Analyses were performed utilizing the GraphPad Prisma version 4.00, and the significance level was considered as p < 0.05.

Results and discussion

Plasma sterol concentrations

Participants’ (n = 38) body weight and BMI remained unaltered throughout the study (Table 3). PS reduced total cholesterol, LDL-C, apoB and triglycerides without affecting HDL-C plasma concentrations. PS supplementation increased plasma level (μg/mL) and ratios (μg/mg cholesterol) of campesterol and sitosterol indicating the participant’s compliance to diets. Plasma lathosterol level (μg/mL) did not change while lathosterol ratios (μg/mg cholesterol) increased due to blockade of intestinal cholesterol absorption by PS. However, the lathosterol/phytosterols ratios decreased due to the predominant PS absorption increase.

Table 3

Body weight, BMI, biochemical analysis, plasma sterol concentrations of patients in the Control and on the PS phases, n = 38.

| Sterols                      | Control     | PS          | p       |
|------------------------------|-------------|-------------|---------|
| Lathosterol                  | 1.53 ± 0.09 | 1.69 ± 0.06 | 0.012   |
| Campesterol                  | 1.96 ± 0.12 | 2.34 ± 0.11 | 0.02    |
| Sitosterol                   | 1.64 ± 0.09 | 2.02 ± 0.09 | <0.001  |
| Lathosterol/ Campesterol ratio| 0.85 ± 0.05 | 0.76 ± 0.03 | <0.001  |
| Lathosterol/ Sitosterol ratio| 1.02 ± 0.05 | 0.88 ± 0.04 | <0.001  |

| Body weight (kg)             | 64.9 ± 10.2 | 65.1 ± 10.3 | 0.08    |
| BMI (kg/m²)                  | 25.4 ± 0.4  | 25.4 ± 0.4  | ns      |
| Total cholesterol (mg/dL)    | 261 ± 7.1   | 244 ± 5.8   | <0.001  |
| LDL-C (mg/dL)                | 46 ± 1.7    | 48 ± 1.9    | ns      |
| ApoB (mg/dL)                 | 183 ± 5.9   | 169 ± 5.2   | 0.001   |
| Triglycerides (mg/dL)        | 126 ± 3.7   | 118 ± 3.2   | 0.006   |

Plasma sterols expressed as µg/mL

Lathosterol                   4.07±1.27    4.07±0.76    ns
Campesterol                   4.95±1.47    5.64±1.47    <0.001
Sitosterol                    4.15±1.24    4.85±1.21    <0.001

LDL-C tertiles selected at baseline

In order to investigate whether the degree of hypercholesterolemia influences the PS response, patients were divided according to tertiles of plasma LDL-C identified at baseline (168 mg/dL and > 187 mg/dL) (Table 4). Data variations on the Control phase minus the PS phase are shown as delta values. PS intake effectively reduced LDL-C and apo B concentrations in both phases but failed to modify triglycerides concentrations. Furthermore, plasma concentrations of lathosterol, campesterol, and sitosterol properly corrected for plasma cholesterol were higher in the LDL-C < 168 than in LDL-C > 187 tertiles during the control phase and failed to change on PS feeding. These results preliminarily indicate similar behavior of the synthesis and absorption markers in the groups that differ by LDL-C concentration.

The similarity of plasma concentrations of lathosterol and PS in the LDL-C < 168 and LDL-C > 187 groups (Table 4) suggests that several factors participate simultaneously in hypercholesterolemia such as variations in synthesis, absorption, and retention of sterols in plasma being often impossible to distinguish the participation of each one of them. This is an example that there are technical limitations on the usefulness of these markers, as previously indicated. Nonetheless, the present investigation confirms previous studies showing that the serum lathosterol-to-cholesterol ratio predicts the serum cholesterol responsiveness on PS feeding. However, during placebo, lack of plasma cholesterol response to PS occurs when the cholesterol synthesis rate is high. The present report differs from the study by Mackay DS et al.28 because the latter investigated obese compared to non-obese while the present study excluded obese participants. Obesity increases cholesterol synthesis. Furthermore, these results contradict a study in children.

BMI, Body Mass Index; LDL-C, Low-Density Lipoprotein Cholesterol; HDL-C, High Density Lipoprotein Cholesterol; apoB, apolipoprotein B. Data shown as means and standard deviation. Student’s t-test.
in which dietary PS altered the concentration of serum PS, but not the serum concentration of cholesterol synthesis precursors. It is possible that in children, the effect of PS on blood cholesterol differs from adults because cholesterol synthesis often is higher in children than in adults.

Non-responders and responders to PS treatment

The authors also examined whether plasma sterol response patterns defined by LDL-C changes distinguish patients’ non-responders (n = 10) and responders (n = 27) to PS treatment (Table 5). Control phase minus PS phase data variations is expressed as delta values. The authors found in the Control phase lathosterol higher in non-responders than in responders to PS. However, on PS feeding, concentrations of lathosterol did not differ between the two groups (non-responders vs. responders). On the other hand, lathosterol percent variation on PS in relation to the Control phase did not vary in non-responders and increased in responders. This means that non-responders, because of high synthesis before PS, may show a higher response to PS treatment, which could not further expand synthesis on PS treatment. Responders synthesize less in the Control phase but expand the synthesis rate on PS.

Since the degree of cholesterol absorption indicated by plasma PS concentration could influence cholesterol synthesis in the Control phase, the authors examined whether plasma sterol response patterns defined by LDL-C changes distinguish patients’ non-responders and responders to PS treatment.

Table 4

Patients’ data during study periods according to the averages of LDL-C tertiles selected at baseline (<168 mg/dL and >187 mg/dL).

| Study periods | LDL-C < 168 | LDL-C > 187 | p       |
|---------------|-------------|-------------|---------|
| LDL-C (mg/dL) |             |             |         |
| Control       | 150 ± 14 (n = 13) | 215 ± 20 (n = 12) | <0.0001 |
| PS            | 148 ± 15 (n = 13) | 192 ± 24 (n = 12) | <0.0001 |
| Delta LDL-C (%) | -0.5 ± 13   | -10.3 ± 12   | ns      |
| Delta LDL-C (mg) | -1.9 ± 18.1 | -23.0 ± 26.1 | 0.0269  |
| ApoB (mg/dL)  |             |             |         |
| Control       | 110 ± 10 (n = 13) | 151 ± 22 (n = 13) | <0.0001 |
| PS            | 112 ± 14 (n = 13) | 131 ± 22 (n = 13) | 0.0120  |
| Delta ApoB (%) | 1.8 ± 10.1  | -12.5 ± 10.2 | 0.0019  |
| Delta ApoB (mg) | 1.8 ± 11.5  | -19.3 ± 17.5 | 0.0013  |
| Triglycerides (mg/dL) | 96 ± 7 (n = 13) | 130 ± 14 (n = 13) | <0.0001 |
| Control       | 115 ± 38 (n = 13) | 148 ± 44 (n = 13) | 0.0472  |
| PS            |             |             |         |
| Delta triglycerides (%) | 22 ± 36    | 15 ± 38    | ns      |
| Delta triglycerides (mg) | 19 ± 42    | 18 ± 47    | ns      |
| Lathosterol (µg/mg cholesterol) | 1.699 ± 0.314 (n = 11) | 1.372 ± 0.303 (n = 12) | 0.0221  |
| Control       | 1.887 ± 0.250 (n = 11) | 1.522 ± 0.233 (n = 12) | 0.0016  |
| PS            |             |             |         |
| Delta lathosterol (%) | 13.73 ± 15.42 | 14.15 ± 22.77 | ns      |
| Delta lathosterol (µg/mg) | 0.197 ± 0.214 | 0.150 ± 0.286 | ns      |
| Campesterol (µg/mg cholesterol) | 2.570 ± 0.633 (n = 11) | 1.391 ± 0.345 (n = 12) | 0.0002  |
| Control       | 2.881 ± 0.794 (n = 11) | 1.941 ± 0.518 (n = 11) | 0.0028  |
| PS            |             |             |         |
| Delta campesterol (%) | 25.43 ± 32.30 | 40.71 ± 20.73 | ns      |
| Delta campesterol (µg/mg) | 0.511 ± 0.704 | 0.550 ± 0.280 | ns      |
| Sitosterol (µg/mg cholesterol) | 1.952 ± 0.445 (n = 11) | 1.196 ± 0.283 (n = 11) | 0.0001  |
| Control       | 2.484 ± 0.518 (n = 11) | 1.693 ± 0.451 (n = 11) | 0.0011  |
| PS            |             |             |         |
| Delta sitosterol (%) | 30.16 ± 26.87 | 41.91 ± 17.95 | ns      |
| Delta sitosterol (µg/mg) | 0.532 ± 0.506 | 0.497 ± 0.242 | ns      |

LDL, Low-Density Lipoprotein; apoB, apolipoprotein B. Control minus phytosterol data variations are expressed as delta values. Data shown as means and standard deviation. Unpaired Student’s t-test.

Table 5

Plasma sterol response patterns defined by LDL-C changes distinguish patients’ non-responders and responders to PS treatment.

| Study periods | Non-responders (n = 11) | Responders (n = 27) | p       |
|---------------|-------------------------|---------------------|---------|
| LDL-C (mg/dL) |                         |                     |         |
| Control       | 171 ± 24                | 191 ± 37            | ns      |
| PS            | 184 ± 29                | 165 ± 32            | ns      |
| Delta LDL-C (%) | 8 ± 5                  | -13 ± 7             | <0.0001 |
| Delta LDL-C (mg/dL) | 14 ± 9                | -26 ± 15            | <0.0001 |
| ApoB (mg/dL)  |                         |                     |         |
| Control       | 122 ± 24                | 129 ± 23            | ns      |
| PS            | 124 ± 21                | 117 ± 19            | ns      |
| Delta ApoB (%) | 3 ± 12                 | -9 ± 11             | 0.0044  |
| Delta ApoB (mg) | 3 ± 14                | -12 ± 16            | 0.0039  |
| Triglycerides (mg/dL) | 110 ± 16              | 113 ± 18            | ns      |
| Control       | 139 ± 50                | 132 ± 41            | ns      |
| PS            | 26 ± 43                 | 19 ± 44             | ns      |
| Delta Triglycerides (%) | 28 ± 49               | 19 ± 45             | ns      |
| Lathosterol (µg/mg cholesterol) | 1.929 ± 0.954 | 1.463 ± 0.363 | 0.0379  |
| Control       | 1.658 ± 0.411           | 1.686 ± 0.344 | ns      |
| PS            | 2.242 ± 0.898           | 1.831 ± 0.610 | ns      |
| Delta lathosterol (%) | 8 ± 16               | 18 ± 19             | 0.0009  |
| Campesterol (µg/mg cholesterol) | 2.168 ± 0.582 | 2.401 ± 0.755 | ns      |
| Control       | 3 ± 25                  | 34 ± 26             | 0.0053  |
| PS            | 1.958 ± 0.860           | 1.529 ± 0.469 | ns      |
| Delta campesterol (%) | 1 ± 26                | 38 ± 23             | 0.0007  |

LDL, Low-Density Lipoprotein. Control minus phytosterol data variations are expressed as delta values. Data shown as means and standard deviation. Unpaired Student’s t-test.
and its response to PS intake, the authors measured plasma PS concentrations before and after PS feeding. The authors noted in the control phase that plasma absorption markers did not differ between responders and non-responders, but lathosterol was higher in non-responders to PS feeding (Table 5). However, unlike non-responders, responders increased the absorption of PS identified by increased plasma PS concentration, most likely due to a small intestinal lumen cholesterol content competing for intestinal absorption with alimentary PS. The authors suggest that elevated synthesis during Control in non-responders makes them resistant to further synthesis rise on PS treatment, whereas responders can expand synthesis under the effect of alimentary PS because they have lower rates of synthesis than non-responders in the Control phase.

Interestingly, in the Control phase, as well as on PS, plasma concentrations of campesterol and sitosterol did not differ between non-responders and responders. However, as occurred for lathosterol, the percent variation of these markers of absorption on PS feeding over the Control phase was significantly greater in the responders than in the non-responders. This is compatible with the responders absorbing more PS than non-responders.

Conclusion

The present study’s data explain decreased intestinal absorption of cholesterol in metabolic syndrome associated with diminished efficiency of food PS esters in reducing blood cholesterol, although the cholesterol synthesis markers were not measured. Such a result may be consequent to elevated cholesterol synthesis in metabolic syndrome.

In summary, responders absorb more PS than non-responders, likely resulting from responders delivering less endogenous cholesterol into the intestinal lumen. The existence of cases responsive to phytosterols resulting from responders delivering less endogenous cholesterol into plasma could influence the interpretation of the results.

Authors’ contributions

Nunes VS: Conceptualization, Methodology, Investigation, Writing - Review & Editing, Ilha AOG; Methodology, Investigation, Writing - Original Draft, Lottenberg AM: Conceptualization, Supervision, Writing - Review & Editing, Ferreira GS: Formal analysis, Bombo RPA: Investigation, Afonso MS: Investigation, Lavrador MSF: Investigation, Machado RM: Investigation, Nakandakare ER: Formal analysis, Validation, Quintao ECR: Conceptualization, Writing - Review & Editing.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

The authors would like to thank UNILEVER (SP, Brazil) for providing soy milk used in this study and the State of São Paulo Research Foundation (FAPESP).

References

1. Lottenberg AMP, Nunes VS, Nakandakare ER, Neves M, Bernik M, Santos JE, et al. Food phytosterol efficiency on the plasma lipid reduction in moderate hypercholesterolemic subjects. Arq Bras Cardiol 2002;79(2):139–42.
2. Acuff RV, Cai DJ, Dong ZP, Bell D. The lipid lowering effect of plant sterol ester capusles in hypercholesterolemic subjects. Lipids Health Dis 2007;6:11.
3. Cater NR, Garcia Garcia AB, Vega GL, Grundy SM. Responsiveness of plasma lipids and lipoproteins to plant stanols esters. Am J Cardiol 2005;96(1A):230–8D.
4. Field FJ, Born E, Mathur SN. Effect of micellar beta-sitosterol on cholesterol metabo- lism in CaCo-2 cells. J Lipid Res 1997;38(2):348–60.
5. Ibeda I, Tanaka K, Sugano M, Vahouny GV, Gallo LL. Inhibition of cholesterol absorption in rats by plant sterols. J Lipid Res 1988;29(12):1573–82.
6. Vanstone CA, Rainei-Sarjaz M, Jones PJH. Injected phytosterols/stanols suppress plasma cholesterol levels in humans. J Nutr 2010;140(1):74.
7. Plat J, Mensink RP. Effects of plant stanol esters on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear blood cells of healthy men and women. Faase 2002;16(2):258–60.
8. Oliveira-Gordy Iba A, Sutti Nunes V, Silva Afonso M, Regina Nakandakare E, da Silva Ferreira G, de Paula Anissi Bombo R, et al. Phytosterols supplementation reduces endothelin-1 plasma concentration in moderately hypercholesterolemic individuals inde- pendently of their cholesterol-lowering properties. Nutrients 2020;12(5):1507.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evalua- tion, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treat- ment Panel III) final report. Circulation 1997;96(5):1343–421.
10. Weingartner O, Lütjohann D, Ji S, Weisshoff N, List F, Sudhop T, et al. Vascular effects of diet supplement with plant sterols. J Am Coll Cardiol 2008;51(16):1553–61.
11. Weingartner O, Weingartner N, Schelleb B, Lütjohann D, Graber S, Schäfers HJ, et al. Alterations in cholesterol homeostasis are associated with coronary heart disease in patients with aortic stenosis. Coron Artery Dis 2009;20(6):376–82.
12. Bombo RPA, Afonso MS, Machado RM, Lavrador MSF, Nunes VS, Quintao ER, et al. Dietary phytosterols do not accumulate in the arterial wall and prevents atherosclero- sis of LDL-ko mice. Atherosclerosis 2013;231(2):442–7.
13. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modifi- cation to reduce cardiovascular risk. Atherosclerosis 2019;294:80–2.
14. Patel MD, Thompson PD. Phytosterols and vascular disease. Atherosclerosis 2006;186:1312–9.
15. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Ef- ficiency and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003;78(9):965–78.
16. Matthian NR, Resteghini N, Robertton M, Ford I, Shepherd J, Packard C, et al. Chole- terol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. J Lipid Res 2010;51(1):222–9.
17. Matthian NR, Pencina M, La Rocque JM, Jacques PF, D’Agostino RB, Schaefer EJ, et al. Alterations in cholesterol absorption/synthesis markers characterize Framingham Off- spring Study participants with CHD. J Lipid Res 2009;50(9):1927–35.
18. Dayspring TD, Varvel SA, Ghaedi L, Thiselton DL, Bruton J, McConnell JP. Biomarkers of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718 patients. J Clin Lipidol 2015;9(5):807–16.
19. Gong Z, Qi V, Zhao F, Liu J, Wang W, Liu J, et al. Association between very low den- sity lipoprotein cholesterol and cholesterol absorption synthesis markers in patients with moderate and high risk of coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi 2015;43(11):936–42.
20. Massnafi S, Plat J, Mensink RP, Baumgartner S. Non-cholesterol sterol concentrations as biomarkers for cholesterol absorption and synthesis in different metabolic disor- ders: a systematic review. Nutrients 2019;11(1):124.
21. Weingartner O, Lütjohann D, Meyer S, Fuhrmann A, Cremers B, Siller-Müller S, et al. Low serum lathosterol levels associate with fatal cardiovascular disease and excess all-cause mortality: a prospective cohort study. Clin Res Cardiol 2019;108(12):1381– 5.
22. MacKay DS, Jones P. Limitations of lathosterol to plant sterol ratios and serum plant sterols as surrogate markers for cholesterol absorption during plant sterol supplemen- tation. J Nutr Metab Cardiovasc Dis 2012;22(9):511–7.
23. Jakub L, Mohammed H, van Dijk TH, Boer T, Turner S, Groen AK, et al. Plasma plant sterol levels serve as poor markers of cholesterol absorption in man. J Lipid Res 2013;54(10):1444–50.
24. Sudhop T, Sahin Y, Lindenhalh B, Hahn C, Lusers C, Berthold HK, et al. Comparison of the hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion. Gut 2002;50(6):860–3.
25. Strandberg TE, Gylling H, Tilvis RS, Miettinen TA. Serum plant and other non-cholester- ols sterols, cholesterol metabolism and 22-year mortality among middle-aged men. Atherosclerosis 2010;210(1):282–7.
26. Lin X, Racette SB, Ma L, Wallendorf M, Davila-Roman VG, Ostlund RE. Endogenous cholesterol excretion is negatively associated with carotid intima-media thickness in humans. Arterioscler Thromb Vasc Biol 2017;37(12):2364–9.
27. Tammi A, Ronneman T, Valinti L, Seppanen R, Rask-Nittala L, Miettinen TA, et al. Die- tary plant sterols alter the serum plant sterol concentration but not the cholesterol pre- cursor sterol concentrations in young children (the STRIP Study). Special Turku Coronary Risk Factor Intervention Project. J Nutr 2001;131(7):1942–5.
28. Mackay DS, Gebauer SK, Eck FK, Boer TJ, Jones PJH. Lathosterol-to-cholesterol ratio in serum predicts cholesterol-lowering response to plant sterol consumption in a dual- center, randomized, single-blind placebo-controlled trial. Am J Clin Nutr 2015;101(3):432–9.
29. Robout TC, Harding S V, Mackay D, Ambewala SS, Jones PJ. High basal fractional cholesterol synthesis is associated with nonresponse of plasma LDL cholesterol to plant sterol therapy. Am J Clin Nutr 2010;92(1):41–6.
30. Quintao ECR. Plasma non-cholesterol sterols as markers of cholesterol synthesis and intestinal absorption: a critical review. Curr Pharm Des 2020;26(40):5152–62.
31. Bachorik PS, Albers JJ. Precipitation methods for quanti- fication of lipoproteins. Methods Enzymol 1986;129:78–100.
32. Friedewald WT, Levy RL, Fredrickson DS. Estimation of the concentration of low-den- sity lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18(6):499–502.
33. Ahmida HSM, Bertucci P, Franzò I, Massoud R, Cortese C, Lala A, et al. Simultaneous determination of plasmatic phytosterols and cholesterol precursors using gas chromatography-mass spectrometry (GC-MS) with selective ion monitoring (SIM). J Chromatogr B 2006;842(1):43–7.

34. Miettinen TA. Gas-liquid chromatographic determination of fecal neutral sterols using a capillary column. Clin Chim Acta 1982;124(2):245–8.

35. Phillips KM, Ruggio DM, Bailey JA. Precise quantitative determination of phytosterols, stanols, and cholesterol metabolites in human serum by capillary gas-liquid chromatography. J Chromatogr B 1999;732(1):17–29.

36. Nunes VS, Leança CC, Panzoldo NB, Parra E, Carita PM, Nakandakare ER, et al. HDL-C concentration is related to markers of absorption and of cholesterol synthesis: Study in subjects with low vs. high HDL-C. Clin Chim Acta 2011;412(1-2):176–80.

37. De Jong A, Plat J, Bast A, Godschaik RWL, Banu S, Mensink RP. Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment. Eur J Clin Nutr 2008;62(2):263–73.

38. Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Bergeron J, Gagné C, et al. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res 2004;45(5):866–72.

39. Simonen P, Gylling H, Miettinen TA. Acute effects of weight reduction on cholesterol metabolism in obese type 2 diabetes. Clin Chim Acta 2002;316(1-2):55–61.

40. Hernandez-Mijares A, Banuls C, Jover A, Sola E, Bellod L, Martinez-Triguero ML, et al. Low intestinal cholesterol absorption is associated with a reduced efficacy of phytosterol esters as hypolipemic agents in patients with metabolic syndrome. Clin Nutr 2011;30(5):604–9.